Biodel

About:

Biodel is a biopharmaceutical company developing and commercializing therapeutics for the treatment of diabetes.

Website: http://www.biodel.com

Top Investors: OrbiMed, Great Point Partners

Description:

Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.

Total Funding Amount:

$48.5M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Danbury, Connecticut, United States

Founded Date:

2003-01-01

Contact Email:

cstmail(AT)continentalstock.com

Founders:

Solomon S. Steiner

Number of Employees:

11-50

Last Funding Date:

2012-06-29

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai